Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 and 65 years old, male or female, of any race~* Definite SLE by meeting either SLICC or ACR Classification Criteria for SLE~* Evidence of a positive ANA (≥1:80 titer) or positive dsDNA antibody test within 6 months of screening~* Clinically mild to moderately active SLE determined by SLEDAI score ≥4 and ≤10 at screening, despite SOC therapy~* If the patient has BILAG A or two BILAG Bs in the renal organ system, he/she must have completed at least 6 months of therapy with either mycophenolate mofetil or cyclophosphamide for the current episode of nephritis~* Able and willing to give written informed consent~Exclusion Criteria:~* Active CNS lupus affecting mental status~* Active lupus nephritis requiring dialysis~* Laboratory exclusions: eGFR \<30, WBC \<2.0/mm3, hemoglobin \<8 g/dL, platelet count \<30,000/mm3, liver enzymes AST or ALT \>4 times upper limit normal; Positive testing for HIV, hepatitis B or hepatitis C~* History of malignant neoplasm within the last 3 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix~* Pregnant or breast feeding; males or females not willing to use adequate contraception~* History of renal transplantation~* Herpes zoster within the past 90 days or any infection requiring hospitalization or intravenous antibiotics within the past 60 days~* Clinically significant EKG or chest X-ray abnormalities~* Any other medical condition, related or unrelated to SLE, that in the opinion of the investigator would render the patient inappropriate or too unstable to complete study protocol~* Use of prednisone \>0.5 mg/kg/day (or equivalent corticosteroid) within 1 month of Baseline visit~* Change or addition to immunosuppressant regimen within 3 months of Baseline visit (except corticosteroids); Use of other experimental therapeutic agents within 3 months of Baseline visit~* Having received belimumab within 3 months of Baseline, or having received rituximab or other B cell depleting biologic therapy within 6 months of Baseline.~* Comorbidities requiring corticosteroid therapy~* Current substance abuse or recent (within 60 days) history of substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Drug: Low Dose Mesenchymal Stem Cells ( MSCs) (Type: EXPERIMENTAL): Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10\^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).